Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NYSE:GKOS

Glaukos Q3 2026 Earnings Date & Estimates

Glaukos logo
$165.37 +4.08 (+2.53%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$165.64 +0.27 (+0.17%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glaukos is scheduled to report Q3 2026 earnings on Wednesday, October 28, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Glaukos in Q3 2026

Glaukos is expected to post earnings of -$0.0959 per share on revenue of $168.01 million. In the same quarter a year earlier Glaukos reported -$0.16 per share on revenue of $133.54 million. Glaukos last reported on July 29, 2026, posting -$0.14 per share and beating the -$0.2105 consensus estimate. Glaukos has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0959
Expected Revenue
$168.01 million
Prior-Year EPS
-$0.16
Prior-Year Revenue
$133.54 million
Expected Revenue Growth
+25.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.14 (Beat by +$0.0705)
Last Quarter Revenue
$185.61 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Glaukos Q3 2026 Earnings FAQ

Glaukos (NYSE:GKOS) has confirmed it will report Q3 2026 earnings on Wednesday, October 28, 2026, after market closes.

Glaukos' Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Glaukos to post earnings of -$0.0959 per share for Q3 2026.

The consensus revenue estimate for Glaukos is $168.01 million for Q3 2026.

Glaukos Earnings Headlines

Glaukos: The Second J-Code Rewrites The Risk Math
October 9 at 11:42 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4953195-glaukos-the-second-j-code-rewrites-the-risk-math
Glaukos Reports Positive Phase 4 Results For IDose TR With Cataract Surgery
October 9 at 12:47 PM  |  rttnews.comhttps://www.rttnews.com/3697870/glaukos-reports-positive-phase-4-results-for-idose-tr-with-cataract-surgery.aspx
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
October 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Glaukos: IDose TR Plus Cataract Surgery Delivers Superior Eye Pressure Reduction In Phase 4 Trial
October 9 at 12:47 PM  |  rttnews.comhttps://www.rttnews.com/3697886/glaukos-idose-tr-plus-cataract-surgery-delivers-superior-eye-pressure-reduction-in-phase-4-trial.aspx
Glaukos Corporation Announces Positive Topline Results From Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose TR In Combination With Cataract Surgery
October 9 at 12:47 PM  |  marketscreener.comM
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
October 9 at 7:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261009307901/en/glaukos-announces-positive-topline-results-from-phase-4-prospective-randomized-controlled-clinical-trial-evaluating-idose%c2%ae-tr-in-combination-with-cataract-surgery/
See More Glaukos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Glaukos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Glaukos and other key companies, straight to your email.

About Glaukos

Glaukos (NYSE:GKOS) is an ophthalmic medical technology company focused on developing and commercializing products intended to preserve and restore vision. The company’s primary business is minimally invasive glaucoma surgery (MIGS), which is designed to reduce intraocular pressure and potentially lessen patients’ dependence on glaucoma medications.

Glaukos’ glaucoma portfolio includes the iStent, iStent inject and iStent infinite systems, which are used in procedures to improve the eye’s natural fluid outflow. The company also develops technologies for corneal health, including products based on corneal cross-linking, a procedure used to strengthen the cornea in patients with conditions such as keratoconus and corneal ectasia.

Founded in 1998 and headquartered in San Clemente, California, Glaukos markets its products through a combination of direct sales and distribution relationships in the United States and international markets. The company is led by Thomas W. Burns, who serves as president and chief executive officer.

View Glaukos Profile
Earnings Tools